Interstitial lung disease and diabetes

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease and its prevalence has been steadily increasing all over the world. DM and its associated micro and macrovascular complications result in significant morbidity and mortality. The microvascular complications are usually manifested as retinopathy, neuropathy, nephropathy and macrovascular complications generally affect the cardiovascular system. In addition to these complications, DM also affects the lungs because of its rich vascularity and abundance in connective tissue (collagen and elastin). DM has been found to cause microvascular complications and proliferation of extracellular connective tissue in the lungs, leading to decline in lung function in a restrictive pattern. Interstitial lung disease (ILD) includes a diverse group of disease conditions characterized by different degrees of inflammation and fibrosis in the pulmonary parenchyma. Idiopathic pulmonary fibrosis (IPF) is one of the common type of idiopathic interstitial pneumonia with a high mortality rate. IPF is characterized by chronic progressive fibrosis leading to progressive respiratory failure. In this review we focus on lung as the target organ in DM and the association of DM and ILD with special emphasis on IPF.

Keywords: Diabetes mellitus, Interstitial lung disease, Idiopathic pulmonary fibrosis, Metformin, Diabetes complications, Pulmonary function test, Restrictive lung disease, Hyperglycemia

Core tip: Diabetes mellitus is a common chronic disease with a high prevalence that leads to multiple complications and comorbidities. Diabetic lung or diabetic pneumopathy is a condition characterized by progressive lung disease caused by the microvascular complications associated with diabetes mellitus. Early recognition of this complication and strict blood sugar control in patients with diabetes can prevent the progression and debilitating symptoms associated with the diabetic lung.